Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to >75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Basilea Pharmaceutica
• Treatments: Alitretinoin; Tretinoin

Criteria

Inclusion Criteria:

• Previous participation in protocol BAP089

• Response of severe, treatment refractory hand dermatitis with mild or moderate, or responding patients who relapsed to 75% of baseline disease

Exclusion Criteria:

• Female patients who are pregnant or who want to become pregnant

• Female patients of child bearing potential who cannot use or who will not commit to using two effective methods of contraception